(Reuters) -Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major ‌step in strengthening the company's domestic production ...

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...

Messenger RNA (mRNA) therapeutics have moved from a promising idea to clinical reality, accelerating vaccine development and opening new paths ...

In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T ...

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the onshoring of drug product manufacturing to its Moderna Technology Center in ...

RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...